Food-Effect Bioavailability Study of AQ-13, a Candidate Antimalarial

Completed · Phase 1

Conditions studied: Malaria

In brief

The purpose of this study is to test the safety of a 2100 mg dose of AQ-13, a new candidate antimalarial active against drug-resistant P. falciparum infection, and to determine the effect of a standard fatty meal on the absorption of the drug from the gut and its blood levels.

Key facts

Study ID

NCT00455494

Run by

Tulane University Health Sciences Center

People needed

14

Starts

2005-01-01

Expected to finish

2006-12-01

Last updated by the study team

2020-12-07

Who can join

Age: 21 and older, up to 45. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Healthy volunteers 21-45 years of age taking no chronic medications other than birth-control pills

You may not qualify if…

• Pregnancy,
• Breast-feeding,
• Chronic disease

Where it is running

• Tulane-LSU General Clinical Research Center — New Orleans, Louisiana, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.